Keros Therapeutics, Inc. (KROS) stock
KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$11.31+1.28 (+12.76%)
Close on Nov 17, 2026Market cap $224.25MP/E –Yield –
Keros Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Keros Therapeutics's enterprise value was -$68.45M on Nov 11, 2026, against $16.78M a year earlier. Over the last 5 years it ranged from -$179.04M to $1.82B, with a median of $648.45M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$68.45M | -151.2% |
| 2025 | Dec 31, 2025 | $133.80M | +47.4% |
| 2024 | Dec 31, 2024 | $90.78M | -89.8% |
| 2023 | Dec 29, 2023 | $892.15M | -11.9% |
| 2022 | Dec 30, 2022 | $1.01B | -11.7% |
| 2021 | Dec 31, 2021 | $1.15B | -11.0% |
| 2020 | Dec 31, 2020 | $1.29B | – |
See a number that looks wrong?